skip banner navigation
National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Angiogenesis Inhibitors




Angiogenesis Inhibitors






NCI Materials






Current Clinical Trials



Page Options
Print This Page  Print This Page
Print This Document  Print This Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Dictionary

Funding Opportunities

NCI Publications

NCI Calendar

Español
NCI Highlights
Chemo Extends Life in Advanced Prostate Cancer

Temozolomide Plus Radiation Helps Brain Cancer

Confirmed: Raloxifene Drops Risk of Breast Cancer

Bortezomib Delays Progression of Multiple Myeloma

Annual Report to the Nation

Past Highlights
Need Help?
Related Pages
Understanding Angiogenesis
An illustrated description of angiogenesis and its importance in cancer research.
Angiogenesis Inhibitors

One promising avenue of cancer research is the study of a group of compounds called angiogenesis inhibitors. These are drugs that block the development of new blood vessels, a process known as angiogenesis.

By blocking the development of new blood vessels, researchers hope to cut off the tumor's supply of oxygen and nutrients. This in turn might stop the tumor from growing and spreading to other parts of the body.

Next Section >

skip footer navigation

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health FirstGov.gov